Evidence map›Paper›PMID 39701036›Full record

ReviewCell systems2024

Emerging approaches for T cell-stimulating platform development.

Emily Ariail, Nikol Garcia Espinoza, A Carson Stephenson, Jamie B Spangler

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cell systems, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Emily AriailDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Nikol Garcia EspinozaTranslational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA.
A Carson StephensonTranslational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA.
Jamie B SpanglerDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, MD, USA; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Molecular Microbiology & Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA. Electronic address: jamie.spangler@jhu.edu.

Funding

Design of de novo interleukin mimics for targeted immunotherapyR01CA240339 · NCI · UNIVERSITY OF WASHINGTON · PI BAKER, DAVID · 2019 to 2023
$2.1M
Biomimetic Matrix for Ex Vivo and In Vivo Activation of T CellsR01EB029341 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI MAO, HAI-QUAN, SCHNECK, JONATHAN P · 2020 to 2023
$1.9M
Immunoengineered nanotechnology for targeted expansion of regulatory T cellsR01EB029455 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI SPANGLER, JAMIE BERTA · 2020 to 2023
$1.7M
NCI NIH HHS R01 CA240339NIBIB NIH HHS R01 EB029341NIBIB NIH HHS R01 EB029455
6 · The paper itself

Abstract

T cells are key mediators of the adaptive immune response, playing both direct and supporting roles in the destruction of foreign pathogenic threats as well as pathologically transformed host cells. The natural process through which T cells are activated requires coordinated molecular interactions between antigen-presenting cells and T cells. Promising advances in biomaterial design have catalyzed the development of artificial platforms that mimic the natural process of T cell stimulation, both to bolster the performance of cell therapies by activating T cells ex vivo prior to adoptive cell transfer and to directly activate T cells in vivo as off-the-shelf treatments. This review focuses on innovative strategies in T cell-stimulating platform design for applications in cancer therapy. We specifically highlight progress in bead-based artificial antigen-presenting cell engineering, hydrogel-based scaffolds, DNA-based systems, alternative polymeric strategies, and soluble activation approaches. Collectively, these advances are expanding the repertoire of tools for targeted immune activation.

Indexed as

T-LymphocytesAnimalsAntigen-Presenting CellsBiocompatible MaterialsCell EngineeringHumansHydrogelsLymphocyte ActivationNeoplasmsBiocompatible MaterialsHydrogelsactivationartificial antigen-presenting cellbiomaterialscancerengineeringhydrogelimmunologyimmunotherapynanoparticlepolymerT cell

Identifiers

PMID39701036
PMCPMC11665896

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.